Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease

(2016) Andrei G. Vlassenko et al.   ANNALS OF NEUROLOGY

Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?

(2016) Piotr Lewczuk et al.   BRAIN

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Partial volume correction in quantitative amyloid imaging

(2015) Yi Su et al.   NEUROIMAGE

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

(2015) Katarzyna Adamczuk et al.   Alzheimers Research & Therapy

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

(2015) Courtney L. Sutphen et al.   JAMA Neurology

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

(2015) Aline Dorey et al.   Frontiers in Neurology

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Quantitative Analysis of PiB-PET with FreeSurfer ROIs

(2013) Yi Su et al.   PLoS One

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

(2011) Leslie M. Shaw et al.   ACTA NEUROPATHOLOGICA

Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data

(2011) Andrei G. Vlassenko et al.   ANNALS OF NEUROLOGY

APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

(2009) John C. Morris et al.   ANNALS OF NEUROLOGY

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

(2009) Nigel J. Cairns et al.   ARCHIVES OF NEUROLOGY

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

(2009) Timo Grimmer et al.   BIOLOGICAL PSYCHIATRY

Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

(2009) Anne M. Fagan et al.   EMBO Molecular Medicine

Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding

(2009) N. Tolboom et al.   JOURNAL OF NUCLEAR MEDICINE

Oligomerization Partially Explains the Lowering of Aβ42 in Alzheimer’s Disease Cerebrospinal Fluid

(2009) Hillevi Englund et al.   Neurodegenerative Diseases

Relationships between biomarkers in aging and dementia

(2009) W. J. Jagust et al.   NEUROLOGY

PET imaging of amyloid deposition in patients with mild cognitive impairment

(2007) Anton Forsberg et al.   NEUROBIOLOGY OF AGING